Alethia Young

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Wednesday that it requested emergency use authorization from the FDA for its investigational coronavirus antibody cocktail. The experimental drug, named REGN-COV2, was in news last week after it was administered to President...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were advancing Monday following a sell-side upgrade and the news of President Donald Trump being administered its investigational COVID-19 antibody cocktail.  The Regeneron Analyst: Cantor Fitzgerald analyst Alethia Young upgraded...

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-stage biopharma following FDA approval of its antibody-drug conjugate Trodelvy as a third-line treatment for metastatic triple-negative...

Gilead Sciences, Inc. (NASDAQ: GILD) reported second-quarter revenues and earnings that trailed expectations. The Gilead Analysts Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and $79 price target for Gilead. Raymond James analyst Steven Seedhouse maintained a Market...

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...

The world is waiting with baited breath for the outcome of two late-stage studies underway in China for Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir as a potential COVID-19 treatment. The Gilead Analyst Cantor Fitzgerald analyst Alethia Young reiterated an Overweight rating on Gilead...

Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir is one of the frontrunners among investigational drugs to treat COVID-19. With a data readout imminent and following an update from CEO Daniel O'Day, an analyst at Cantor Fitzgerald looked at what could lie ahead for the company with...

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced additional positive data from its pivotal Phase 3 REGENERATE trial Wednesday. The trial is evaluating Intercept's obeticholic acid, or OCA, in patients with liver fibrosis due to non-alcoholic steatohepatitis, or NASH. The new data...

Puma Biotechnology Inc (NASDAQ: PBYI) announced fourth-quarter results and 2019 guidance Thursday that were ahead of expectations, boosting confidence in Nerlynx achieving a global product revenue estimate of $683 million in 2023, according to Cantor Fitzgerald. The Analyst Cantor Fitzgerald...

Sarepta Therapeutics Inc (NASDAQ: SRPT) reported fourth-quarter results Wednesday alongside positive results for its muscular dystrophy gene therapy candidate. The Analysts Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate. Cantor Fitzgerald analyst...

Viking Therapeutics Inc (NASDAQ: VKTX), which focuses on therapies for metabolic and endocrine disorders, recently presented Phase 2 data for its non-alcoholic fatty liver disease, or NAFLD, treatment candidate VK2809 at the annual meeting of the American Association for the Study of Liver...

Mesoblast limited (ADR) (NASDAQ: MESO), a developer of adult stem cell-based products, has struggled to meet key clinical timelines and lost a key partnership with Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA) for a heart failure program, according to Credit Suisse.  The...